Atopic Dermatitis Enrollment Form

Fax Referral To: 1-800-323-2445
Email Referral To: Customer.ServiceFax@CVSHealth.com
Phone: 1-800-237-2767

Six Simple Steps to Submitting a Referral

1 PATIENT INFORMATION *(Complete or include demographic sheet)*

Patient Name: ____________________ DOB: ______________ Gender: ☐ Male ☐ Female
Address: ____________________City, State, ZIP Code: ____________________
Preferred Contact Methods: ☐ Phone (to primary # provided below) ☐ Text (to cell # provided below) ☐ Email (to email provided below)
Note: Carrier charges may apply. By providing the phone number(s) and email address above, you are consenting to receive automated calls, emails and/or text messages from CVS Specialty® about your prescription(s), account, and health care. Standard data rates apply. Message frequency varies. If unable to contact via text or email, Specialty Pharmacy will attempt to contact by phone.
Primary Phone: ____________________ Alternate Phone: ____________________
Email: ____________________ Last Four of SSN: __________ Primary Language: ____________________
Parent/Caregiver/Legal Guardian Name (Last, First): ______________**Relationship to patient**: ____________________

2 PRESCRIBER INFORMATION

Prescriber's Name: ____________________ State License #: ____________________
NPI #: __________ DEA #: __________ Group or Hospital: ____________________
Address: ____________________ City, State, ZIP Code: ____________________
Phone: ______________ Fax______________ Contact Person: ____________________ Contact's Phone: ______________

3 INSURANCE INFORMATION

Please fax copy of prescription and insurance cards with this form, if available (front and back)

4 DIAGNOSIS AND CLINICAL INFORMATION

Needs by Date: ____________________ Ship to: ☐ Patient ☐ Office ☐ Other:______________
Diagnosis (ICD-10):
☐ L20.9 Atopic Dermatitis, Unspecified ☐ Other Code: ______ Description ____________________
Patient Clinical Information:
Allergies: ____________________ Weight: _____lb/kg Height: _____in/cm TB Test Result: __________ Date: ______

©2024 CVS Specialty and/or one of its affiliates. 75-41356A 1/19/24

Atopic Dermatitis Enrollment Form

Please Complete Patient , Prescriber and Patient Clinical Information

Patient Name: ______________________________ Patient DOB: ____________________ Patient Phone: ______________________

Prescriber Name: ____ Prescriber Phone: ____________________________

Patient Clinical Information:

Allergies: ____

Weight:______________lb/kg Height:______________In/cm TB Test Result: ____________________ Date:__________

5 PRESCRIPTION INFORMATION

MEDICATION	STRENGTH	DOSE & DIRECTIONS	QUANTITY/REFILLS
☐ Adbry	☐ 2x150 mg/mL PFS ☐ 4x150 mg/mL PFS	Loading Dose: ☐ Inject 600 mg (4x150 mg/mL) SC on Day 1 ☐ Inject 300 mg (2x150 mg/mL) SC on Day 1	Quantity: ☐ 2x150 mg/mL PFS ☐ 4x150 mg/mL PFS Refill: 0
	☐ 2x150 mg/mL PFS ☐ 4x150 mg/mL PFS	Maintenance Dose: ☐ Inject 300 mg (2X150 mg/mL) SC every other week starting on Day 15 ☐ Inject 300 mg (2X150 mg/mL) SC every 4 weeks ☐ Inject 150 mg (1X150 mg/mL) SC every other week starting on Day 15	Quantity: ☐ 28 days ☐ 84 days Refill: ________
☐ Cibinqo	☐ 50 mg ☐ 100 mg ☐ 200 mg	☐ Take 1 tablet by mouth once daily ☐ Other:________________________________	Quantity: __________ Refills: ___________
☐ Dupixent	**For use in patients ≥ 6 months and older:** ☐ 200 mg/1.14 mL (Carton of two pre-filled syringes with needle shield) ☐ 300 mg/2 mL (Carton of two pre-filled syringes with needle shield) **For use in patients ≥ 2 years of age and older:** ☐ 200 mg/1.14 mL (Carton of two single dose pre-filled pens) ☐ 300 mg/2 mL (Carton of two single dose pre-filled pens)	**Adult Patients:** ☐ 600 mg (two 300 mg injections) subcutaneously on Day 1, then 300 mg subcutaneously every other week thereafter **Pediatric Patients (6 months to 5 years of age):** 5 to less than 15 kg: ☐ 200 mg (one pre-filled syringe) every 4 weeks 15 to less than 30 kg: ☐ 300 mg (one pre-filled syringe) every 4 weeks **Pediatric Patients (6 years to 17 years of age)** 15 to less than 30 kg: ☐ 600 mg (two 300 mg injections) subcutaneously on Day 1, then 300 mg subcutaneously every 4 weeks thereafter 30 to less than 60 kg: ☐ 400 mg (two 200 mg injections) subcutaneously on Day 1, then 200 mg subcutaneously every 2 weeks thereafter 60 kg or more: ☐ 600 mg (two 300 mg injections) subcutaneously on Day 1, then 300 mg subcutaneously every 2 weeks thereafter	Quantity: __________ (# of injections) Refills: ___________
☐ Rinvoq	☐ 15 mg ☐ 30 mg	☐ Take 1 tablet by mouth once daily ☐ Other:________________________________	Quantity: _________ Refills: ___________
☐ Other: ___________	☐ Other: ____________________	☐ Other: ________________________________	Quantity: ________ Refills: ___________

☐ Patient is interested in patient support programs **STAMP SIGNATURE NOT ALLOWED** Ancillary supplies and kits provided as needed for administration

6 PRESCRIBER SIGNATURE REQUIRED (STAMP SIGNATURE NOT ALLOWED)

"Dispense As Written" / Brand Medically Necessary / Do Not Substitute / No Substitution / DAW / May Not Substitute **Prescriber's Signature: _______________________ Date: ________**	May Substitute / Product Selection Permitted / Substitution Permissible **Prescriber's Signature: _____________________ Date: ______**

CA, MA, NC & PR: Interchange is mandated unless Prescriber writes the words "**No Substitution**" _______________ **ATTN: New York and Iowa providers,** please submit electronic prescription

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments.
Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information.
This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Specialty and/or one of its affiliates.